Company Profile: Achillion Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development and commercialization of innovative treatments for infectious diseases.
Share Price: $3.03 (Dec. 17)
2010 Stock Performance: -2.6%
Analyst Consensus: Seven research analysts have a "buy" rating on Achillion shares. Another two analysts suggesting holding onto shares, while no firm has a "sell" rating on the stock.
Bullish Case: Wedbush analyst Katherine Xu in an Oct. 28 research note reiterated an outperform rating on Achilion with a $5 price target. Xu notes Achillion's drug pipeline, which could "position the company well for further advancement or acquisition, if all goes well."
"We believe Achillion's pipeline, while early, is well-differentiated and broad," Xu wrote. "The dataset on the portfolio the company plans to deliver will build towards a significant value inflection in the next two years, in our opinion."
Market Data 
Markets 
AI
